0001615774-18-011317.txt : 20181025
0001615774-18-011317.hdr.sgml : 20181025
20181025160945
ACCESSION NUMBER: 0001615774-18-011317
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20181025
DATE AS OF CHANGE: 20181025
EFFECTIVENESS DATE: 20181025
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tivorsan Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001705703
IRS NUMBER: 770702642
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1217
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-324385
FILM NUMBER: 181139001
BUSINESS ADDRESS:
STREET 1: 3 DAVOL SQUARE, A301
CITY: PROVIDENCE
STATE: RI
ZIP: 02903
BUSINESS PHONE: 310-424-1986
MAIL ADDRESS:
STREET 1: 2049 CENTURY PARK EAST, SUITE 320
CITY: LOS ANGELES
STATE: CA
ZIP: 90067
D
1
primary_doc.xml
X0708
D
LIVE
0001705703
Tivorsan Pharmaceuticals, Inc.
2049 CENTURY PARK EAST
SUITE 320
LOS ANGELES
CA
CALIFORNIA
90067
310-424-1999
DELAWARE
None
None
Corporation
true
Michael
Meyers
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Executive Officer
John
Nicholson
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Director
Commission above does not include 9,061 shares of common stock and warrants to purchase 36,250 shares of common stock with an exercise price of $1.60.
Justin
Fallon
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Director
Joel
Braunstein
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Director
Jay
Venkatesan
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Director
James
Connolly
2049 Century Park East
Suite 320
Los Angeles
CA
CALIFORNIA
90067
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2016-01-29
false
true
true
true
false
5000
T.R. Winston & Company, LLC
10571
None
None
2049 CENTURY PARK EAST
SUITE 320
LOS ANGELES
CA
CALIFORNIA
90067
CA
CALIFORNIA
CT
CONNECTICUT
DE
DELAWARE
IL
ILLINOIS
MA
MASSACHUSETTS
NY
NEW YORK
PA
PENNSYLVANIA
RI
RHODE ISLAND
TX
TEXAS
false
2938000
2938000
0
false
35
14500
0
Commission above does not include 9,061 shares of common stock and warrants to purchase 36,250 shares of common stock with an exercise price of $1.60.
0
false
Tivorsan Pharmaceuticals, Inc.
/s/ Michael Meyers
Michael Meyers
Chief Executive Officer
2018-10-25